Palvella Therapeutics, Inc. Shareholders' Equity
Palvella Therapeutics, Inc. (PVLA) had Shareholders' Equity of $216.87 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $216.87M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $232.31M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $27.98M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $38.68M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $216.87M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $232.31M 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $27.98M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $38.68M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $47.78M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $55.58M 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $62.61M 10-Q · filed 2026-08-04 | |
| 2024-09-30 | -$87.40M 10-Q · filed 2025-11-12 | $16.27M 10-Q · filed 2024-11-13 |
| 2024-06-30 | -$80.83M 10-Q · filed 2025-11-12 | $18.70M 10-Q · filed 2024-08-14 |
| 2024-03-31 | -$76.87M 10-Q · filed 2025-11-12 | $21.96M 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$74.48M 10-K · filed 2026-03-31 | $26.76M 10-K · filed 2024-03-29 |
| 2023-09-30 | $30.51M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $40.50M 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $15.46M 10-Q · filed 2024-08-14 | |
| 2022-12-31 | -$93.78M 10-K · filed 2025-03-31 | $27.93M 10-K · filed 2023-03-31 |
| 2022-09-30 | $35.77M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $44.37M 10-Q · filed 2023-11-14 | |
| 2022-03-31 | $53.45M 10-Q · filed 2023-08-10 | |
| 2021-12-31 | $50.76M 10-K · filed 2024-03-29 | |
| 2021-09-30 | $53.85M 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $46.72M 10-Q · filed 2022-11-04 | |
| 2021-03-31 | $38.24M 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $31.03M 10-K · filed 2023-03-31 | |
| 2020-09-30 | $43.69M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $46.67M 10-Q · filed 2021-11-02 | |
| 2020-03-31 | $49.81M 10-Q · filed 2021-08-05 | |
| 2019-12-31 | $51.35M 10-K · filed 2022-03-02 | |
| 2019-09-30 | $20.64M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $19.48M 10-Q · filed 2020-11-04 | |
| 2019-03-31 | $30.16M 10-Q · filed 2020-08-10 | |
| 2019-01-01 | $38.29M 10-K · filed 2020-03-13 | |
| 2018-12-31 | $39.94M 10-K · filed 2021-03-31 | |
| 2018-09-30 | $50.26M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $55.31M 10-Q · filed 2019-11-12 | $55.32M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $50.69M 10-Q · filed 2019-08-09 | $50.69M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $11.52M 10-K · filed 2020-03-13 | |
| 2017-09-30 | $4.56M 10-Q · filed 2017-11-13 | |
| 2017-06-30 | $9.33M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $18.04M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $25.23M 10-K · filed 2019-03-18 | $25.23M 10-K · filed 2017-03-30 |
| 2016-09-30 | $31.48M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $37.29M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $27.18M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $31.13M 10-K · filed 2018-03-15 | $31.13M 10-K · filed 2016-03-23 |
| 2015-09-30 | $33.65M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $11.15M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $14.23M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $18.01M 10-K · filed 2017-03-30 | $18.01M 10-K · filed 2015-03-30 |
| 2014-06-30 | $10.01K 10-Q · filed 2014-12-12 | |
| 2013-12-31 | $585.01K 10-K · filed 2016-03-23 | |
| 2012-12-31 | $495.70K 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |